Of note, basal and ERBB2 subgroups have been found to respond better to 5-fluorouarcil, doxorubicin and cyclophosphamide chemotherapy relative to other breast cancer subgroups (Rouzier et al, 2005). Here, ERBB2 is linked to breast carcinoma.